Chlorambucil

Generic Name: Chlorambucil

Brand Names: Leukeran

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₉Cl_₂NO_₂

CAS Number: 305-03-3

Unique Ingredient Identifier: 18D0SL7309

Background: A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

Indication: For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.

Associated Conditions: Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Indolent Lymphoma, Lymphoma, Lymphoma, Diffuse, MALT Lymphoma, Mantle Cell Lymphoma (MCL), Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Waldenström's Macroglobulinemia (WM), Giant follicular lymphoma

Clinical Trials

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Phase 3

Recruiting

Conditions: CLL/SLL

Interventions: Drug: Lisaftoclax (APG-2575)
Drug: Fludarabine
Drug: Cyclophosphamide，CTX
Drug: Acalabrutinib
Drug: Rituximab
Drug: Chlorambucil

First Posted Date: 2024-03-20

Last Posted Date: 2024-05-29

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 344

Registration Number: NCT06319456

Locations: 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

and more 3 locations

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Phase 3

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Chlorambucil
Drug: ICP-022
Drug: Rituximab

First Posted Date: 2020-10-08

Last Posted Date: 2023-06-05

Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Target Recruit Count: 218

Registration Number: NCT04578613

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 53 locations

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Untreated Chronic Lymphocytic Leukemia

Interventions: Drug: Acalabrutinib
Drug: Rituximab
Drug: Chlorambucil

First Posted Date: 2019-08-30

Last Posted Date: 2025-04-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 155

Registration Number: NCT04075292

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 3

Active, not recruiting

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Ibrutinib
Drug: Chlorambucil
Drug: Venetoclax
Drug: Obinutuzumab
Drug: Ibrutinib (as Subsequent Therapy)

First Posted Date: 2018-03-12

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 211

Registration Number: NCT03462719

Locations: 🇵🇱
Wojewodzki Szpital Specjalistyczny im Janusza Korczaka, Slupsk, Poland
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

and more 84 locations

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Chlorambucil
Drug: Obinutuzumab

First Posted Date: 2016-09-26

Last Posted Date: 2022-06-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT02915224

Locations: 🇬🇷
Attiko Hospital; Haematology Clinic, Athens, Greece
🇬🇷
General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, Greece
🇬🇷
AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece

and more 8 locations

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: Ublituximab
Biological: Obinutuzumab
Drug: Chlorambucil
Drug: TGR-1202

First Posted Date: 2015-11-23

Last Posted Date: 2024-12-13

Lead Sponsor: TG Therapeutics, Inc.

Target Recruit Count: 603

Registration Number: NCT02612311

Locations: 🇬🇧
TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Obinutuzumab
Drug: Acalabrutinib
Drug: Chlorambucil

First Posted Date: 2015-06-19

Last Posted Date: 2025-03-11

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 535

Registration Number: NCT02475681

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Phase 1

Terminated

Conditions: B-Cell Chronic Lymphocytic Leukemia

Interventions: Drug: Chlorambucil
Drug: Obinutuzumab
Drug: Placebo
Other: Standard Premedication
Drug: Tocilizumab

First Posted Date: 2015-01-12

Last Posted Date: 2021-04-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT02336048

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸
Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy

and more 11 locations

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia
Small-Cell Lymphoma

Interventions: Drug: Ibrutinib
Drug: Obinutuzumab
Drug: Chlorambucil

First Posted Date: 2014-10-15

Last Posted Date: 2020-09-21

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 229

Registration Number: NCT02264574

Locations: 🇬🇧
Site Reference ID/Investigator# 0867, Harlow, Essex, United Kingdom
🇦🇺
Site Reference ID/Investigator# 0888, Ballarat, Victoria, Australia
🇦🇹
Site Reference ID/Investigator# 0869, Salzburg, Austria

and more 68 locations

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Venetoclax
Drug: Chlorambucil
Drug: Obinutuzumab

First Posted Date: 2014-09-17

Last Posted Date: 2025-02-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 445

Registration Number: NCT02242942

Locations: 🇦🇺
Tweed Hospital, Tweed Heads, New South Wales, Australia
🇦🇺
The Townsville Hospital, Douglas, Queensland, Australia
🇦🇺
Princess Alexandra Hospital Woolloongabba, Woolloongabba, Queensland, Australia

and more 110 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy